Real-world Data: MCL2 Protocol Demonstrates Excellent Treatment Results Among Patients With Mantle Cell Lymphoma Not Fulfilling the Original Trial Inclusion Criteria-Reference-Cited by-同舟云学术

Real-world Data: MCL2 Protocol Demonstrates Excellent Treatment Results Among Patients With Mantle Cell Lymphoma Not Fulfilling the Original Trial Inclusion Criteria

Published:2023-09-07 Issue:10 Volume:7 Page:e954
ISSN:2572-9241
Container-title:HemaSphere
language:en
Short-container-title:

Author:

Harmanen Minna¹,Klaavuniemi Tuula²,Sorigue Marc³,Khan Madiha¹,Prusila Roosa⁴⁵,Kari Esa⁶,Alanne Erika⁷,Rajamäki Aino¹⁶⁸,Sunela Kaisa⁶⁹,Jukkola Arja⁶,Jantunen Esa¹⁰¹¹,Sancho Juan-Manuel³,Ketola Sanna⁸,Kuitunen Hanne⁵,Selander Tuomas¹²,Rönkä Aino¹³,Kuittinen Outi¹⁵

Affiliation:

1. Department of Oncology, Faculty of Health Medicine, Institute of Clinical Medicine, Kuopio University Hospital Cancer Center, Kuopio, Finland

2. Department of Oncology, Mikkeli Central Hospital, Southern Savonia Municipality District, Mikkeli, Finland

3. Department of Hematology, ICO-Badalona, Hospital Germans Trias i Pujol, IJC, LUMN, Badalona, Spain

4. Department of Pediatrics, Kuopio University Hospital, Kuopio, Finland

5. Cancer Center and Medical Research Center, Oulu University Hospital, Oulu, Finland

6. Department of Oncology, Tampere University Hospital, Tampere Cancer Center, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland

7. Department of Oncology and Radiotherapy, Turku University Hospital, Western Finland, Cancer Center, Turku, Finland

8. Department of Oncology, Hospital Nova of Central Finland, Jyväskylä, Finland

9. Finnish Medicines Agency, Tampere, Finland

10. Institute of Clinical Medicine, University of Eastern Finland and Department of Medicine, North Carelia Central Hospital, Joensuu, Finland

11. Department of Medicine, Kuopio University Hospital, Kuopio, Finland

12. Science Service Center, Kuopio University Hospital, Kuopio, Finland

13. Department of Oncology and Radiotherapy, Kuopio University Hospital, Kuopio, Finland

Publisher

Wiley

Subject

Hematology

Reference11 articles.

1. Survival trends in patients under age 65 years with mantle cell lymphoma, 1995-2016: a SEER-based analysis.;Wu;Front Oncol,2020

2. Update on mantle cell lymphoma.;Maddocks;Blood,2018

3. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group.;Geisler;Blood,2008

4. 15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau.;Eskelund;Br J Haematol,2016

5. CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d’Etude des Lymphomes de l’Adulte.;Delarue;Blood,2013